Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER vs KAON CL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium ion is essential for normal cell function, including muscle contraction, nerve transmission, and blood coagulation. It acts as a positive inotrope by increasing myocardial contractility and also corrects hypocalcemia.
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
Cardiac resuscitation (e.g., asystole, pulseless electrical activity) due to hyperkalemia, hypocalcemia, or calcium channel blocker overdose,Severe hypocalcemia,Treatment of hypermagnesemia,Treatment of calcium channel blocker overdose,Cardiopulmonary bypass,Intraoperative floppy iris syndrome (off-label)
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitalis and diuretics,Off-label: prevention of hypokalemia in patients on potassium-wasting diuretics
IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min. May be repeated as needed based on serum calcium levels and clinical response.
Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
2-4 hours in patients with normal renal function; prolonged in renal impairment.
Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease).
Calcium chloride dissociates to release calcium ions which are primarily regulated by the kidney; no significant hepatic metabolism.
Not significantly metabolized; primarily excreted unchanged by the kidneys, with minor fecal elimination.
Primarily renal (80-90% as ionized calcium); minor fecal elimination (<10%).
Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Approximately 45-50% bound primarily to albumin.
Minimal protein binding (<1%); not significantly bound to plasma proteins.
0.5-0.6 L/kg; primarily distributed in extracellular fluid.
Approximately 0.5–0.8 L/kg; distributes mainly in extracellular fluid, with minimal intracellular penetration.
Not applicable; administered only intravenously. Oral calcium salts have variable bioavailability (25-40%).
Oral bioavailability is ~90-100% due to complete absorption of potassium chloride; food may slightly reduce absorption but overall high.
GFR 30-60 m L/min: Use with caution; monitor serum calcium and phosphate levels. GFR <30 m L/min: Avoid use or use only if benefit outweighs risk; reduce dose by 50% and monitor serum calcium and phosphate closely.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: use with caution, reduce dose and monitor serum potassium; GFR < 10 m L/min: contraindicated due to risk of hyperkalemia.
No dose adjustment recommended for Child-Pugh Class A or B. Child-Pugh Class C: Use with caution; monitor serum calcium and cardiac function due to potential for accumulation of calcium and effects on myocardial contractility.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of hyperkalemia from potential electrolyte disturbances.
IV: 0.2 m L/kg (20 mg/kg) of 10% solution, administered slowly at a rate not exceeding 0.5-1 m L/min. Dose may be repeated if needed. Maximum single dose: 1 g (10 m L).
Dose determined by physician based on serum potassium levels and underlying condition; typical oral dose: 1-3 m Eq/kg/day in divided doses, not to exceed 1 m Eq/kg per single dose or maximum 4 m Eq/kg/day. Extended-release tablets not recommended for children < 12 years unless specifically directed.
No specific dose adjustment, but consider reduced renal function common in elderly; use lowest effective dose and monitor serum calcium, phosphate, and cardiac status. Infusion rate should be slow (0.5-1 m L/min) to avoid adverse effects.
Elderly patients often have reduced renal function and may require lower starting doses (e.g., 20 m Eq twice daily) with close monitoring of serum potassium and renal function. Avoid if e GFR < 30 m L/min/1.73 m².
Do not administer by intracardiac injection due to risk of myocardial rupture and cardiac arrest.
Potassium chloride can cause hyperkalemia and cardiac arrest if administered too rapidly or in excessive doses. Avoid use in patients with severe renal impairment or conditions that predispose to hyperkalemia.
Extravasation can cause tissue necrosis; administer slowly to avoid hypercalcemia; use with caution in digitalis toxicity as hypercalcemia potentiates digoxin toxicity; monitor serum calcium levels; avoid in patients with renal failure unless severe hypocalcemia exists.
Hyperkalemia risk, especially in renal impairment,Avoid solid oral forms in patients with esophageal stricture or delayed GI transit,May exacerbate metabolic alkalosis,Monitor serum potassium levels regularly
Hypercalcemia, ventricular fibrillation during cardiac arrest, concurrent digitalis therapy (relative), patients with known hypersensitivity to calcium salts.
Hyperkalemia,Severe renal impairment (oliguria, anuria, or azotemia),Concurrent use of potassium-sparing diuretics or ACE inhibitors (with caution),Untreated Addison's disease,Acute dehydration or heat cramps
Avoid calcium-fortified foods and dairy products if serum calcium is elevated. High doses of vitamin D can increase calcium absorption, leading to hypercalcemia. Caffeine and alcohol may increase urinary calcium excretion, potentially reducing efficacy. Oxalate-rich foods (spinach, rhubarb) and phytate-rich foods (whole grains) bind calcium and may reduce absorption, but this is less relevant with IV administration.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium, as they may increase risk of hyperkalemia. Taking with food reduces gastrointestinal irritation.
No evidence of teratogenicity in animal studies; calcium chloride is a normal blood constituent. First trimester: no known risk. Second and third trimesters: use only if clearly needed; high doses may cause hypercalcemia in fetus (e.g., hypotonia, poor feeding). Intravenous administration near term may suppress fetal parathyroid function.
Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.
Calcium is excreted in breast milk but in normal physiological amounts. M/P ratio not established; supplemental calcium likely safe but high IV doses may increase milk calcium concentration. Monitor infant for hypercalcemia with prolonged high-dose maternal therapy.
Potassium is a normal component of breast milk. Exogenous potassium does not significantly alter milk levels. M/P ratio not established; considered compatible with breastfeeding.
No specific dose adjustment required; pharmacokinetic changes in pregnancy (e.g., increased plasma volume) may necessitate higher doses to achieve desired serum calcium levels, but titrate to effect and serum calcium monitoring. Avoid bolus administration during labor; use slow IV infusion.
No dose adjustment required for potassium chloride in pregnancy; pharmacokinetics are substantially unchanged.
Calcium chloride provides approximately 3 times more elemental calcium per m L than calcium gluconate. Due to its high osmolality (approx. 2000 m Osm/L), it is a severe vesicant; central line administration is strongly preferred to prevent tissue necrosis if extravasation occurs. For peripheral IV, use a large bore vein with good blood flow and avoid hand/wrist veins. In cardiac arrest (e.g., hyperkalemia, calcium channel blocker overdose), give 10 m L of 10% solution (1 g) IV push; may repeat every 10 minutes if needed. Monitor serum calcium, magnesium, and phosphate levels; correct hypomagnesemia before calcium therapy to prevent refractory hypocalcemia. Contraindicated in digitalis toxicity (can precipitate fatal arrhythmias). Not for IM or SC use.
KAON CL is a potassium chloride supplement. Monitor serum potassium levels frequently, especially in patients with renal impairment or those on ACE inhibitors/ARBs, NSAIDs, or potassium-sparing diuretics to avoid hyperkalemia. Administer with food to minimize gastrointestinal irritation. Do not crush or chew extended-release formulations; swallow whole. Hypomagnesemia can cause refractory hypokalemia; check magnesium levels if potassium repletion fails.
Report any burning, pain, or swelling at the IV site immediately.,This medication increases calcium levels; do not take additional calcium supplements or antacids without doctor approval.,Calcium can interfere with the absorption of certain antibiotics (tetracyclines, fluoroquinolones) and thyroid medications; separate doses by at least 2-4 hours.,Avoid excessive intake of vitamin D or calcium-rich foods unless directed by your doctor.,Seek emergency care if you experience chest pain, irregular heartbeat, or muscle cramps.
Take this medication with a full glass of water and with food to reduce stomach upset.,Do not crush, chew, or break extended-release tablets; swallow them whole.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium such as muscle weakness, irregular heartbeat, numbness/tingling, or confusion.,Keep all appointments for blood tests to monitor kidney function and potassium levels.
"Calcium chloride, an intravenous calcium salt, directly increases serum ionized calcium levels, which can antagonize the pharmacodynamic effects of the calcium channel blocker manidipine. Manidipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Elevated extracellular calcium from calcium chloride administration can overcome this blockade, potentially diminishing the antihypertensive efficacy of manidipine and increasing the risk of hypertensive urgency or elevated blood pressure."
"Calcium chloride, a source of calcium ions, can chelate with bisphosphonates such as risedronic acid in the gastrointestinal tract, forming insoluble complexes that reduce the oral absorption of risedronic acid. This interaction may lead to decreased serum concentrations of risedronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption. Patients may experience reduced bone mineral density or increased risk of fractures if the interaction is significant."
"Calcium chloride, a source of calcium ions, can chelate alendronic acid (a bisphosphonate) in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of alendronic acid. This interaction can significantly decrease the systemic bioavailability and serum concentration of alendronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption and treating osteoporosis. Clinically, patients may experience reduced bone mineral density improvement or increased fracture risk if the drugs are co-administered."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER vs KAON CL, answered by our medical review team.
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Calcium ion is essential for normal cell function, including muscle contraction, nerve transmission, and blood coagulation. It acts as a positive inotrope by increasing myocardial contractility and also corrects hypocalcemia.. KAON CL is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER and KAON CL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is: IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min. May be repeated as needed based on serum calcium levels and clinical response.. The standard adult dose of KAON CL is: Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER and KAON CL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies; calcium chloride is a normal blood constituent. First trimester: no known risk. Second and third trimesters: use only if clearly ne. KAON CL is classified as Category C. Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.